FDA Approves Unknown Drug — NEPHRON
NEPHRON announced yesterday the FDA approval of its proposed ANDA215217 to market [insert Substance name], a strategic move expected to significantly intensify competition in the […
SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
NEPHRON announced yesterday the FDA approval of its proposed ANDA215217 to market [insert Substance name], a strategic move expected to significantly intensify competition in the […
NDA220736 cleared by FDA on June 22, 2026 for its proprietary brand, NDA220736, which received FDA clearance on June 22, 2026, offering Galderma Laboratories a strategic dual-actio…
# FDA Approves Generic Clonazepam ANDA for Advagen Pharma Ltd Advagen Pharma Ltd has received FDA approval for its abbreviated new drug application (ANDA216988) for generic clonaz…
# FDA Approves Alembic's Generic Drug Application Alembic has received FDA approval for generic drug application ANDA216370, expanding the company's portfolio in the competitive g…
# FDA Approves New Generic Drug Application for Micro Labs Micro Labs received FDA approval for ANDA220104 on May 19, 2026, expanding its generic pharmaceutical portfolio and posi…
# FDA Approves QUAGEN's ANDA Application, Expanding Generic Drug Portfolio QUAGEN has received FDA approval for ANDA216910, strengthening its position in the generic pharmaceutica…
# FDA Approves Accord BioPharma Biologic; Entry Expected to Intensify Market Competition Accord BioPharma Inc. has received FDA approval for a new biologic therapeutic under BLA76…
# FDA Approves Jubilant Generics ANDA Application Jubilant Generics received FDA approval for ANDA210329 on May 15, 2026, positioning the company to capture market share in the ge…
# FDA Approves Dr. Reddy's Generic Drug Application Dr. Reddy's Laboratories has received FDA approval for ANDA214733, expanding its generic pharmaceutical portfolio and positioni…
Zydus Lifesciences announced that FDA has granted approval for its generic drug submission referenced by ANDA217758, potentially impacting the market share of the branded equivalen…
DR REDDYS announced the FDA's approval of its ANDA215820 on May 15, 2026, which is expected to broaden its commercial footprint once the product launches. This regulatory milestone…
# FDA Approves Amneal Pharmaceuticals' Generic Tretinoin Topical Formulation Amneal Pharmaceuticals NY LLC received FDA approval for its generic tretinoin topical formulation (AND…
# FDA Approves Renova Pharmaceuticals' Generic L-Glutamine Oral Formulation Renova Pharmaceuticals LLC has received FDA approval for its generic L-glutamine oral formulation (ANDA…
# FDA Approves Chiesi's New Drug Application NDA219622 Chiesi Pharmaceuticals has received FDA approval for a new drug candidate under application NDA219622, marking an addition t…
Ionetix Corporation announced the FDA approval of Gallium Ga-68 Gozetotide, a generic version of the prostate cancer imaging agent PSMA-11, which is expected to intensify price com…
On May 13, 2026, BEONE MEDICINES USA may experience a significant market impact with the likely approval of a new drug, though the specific substance and indication remain undisclo…
Caplin Steriles Limited has received FDA approval for its ANDA220068 application, granting it authorization to market foscarnet sodium injection in the United States. This approval…
# FDA Approves Estradiol Transdermal Patch from Encube Ethicals Encube Ethicals, Inc. received FDA approval for its generic estradiol transdermal patch (ANDA218214), expanding the…
# FDA Approves Micro Labs Generic Drug Application Micro Labs has received FDA approval for its abbreviated new drug application (ANDA 218558), expanding the company's generic pha…
# FDA Approves Sandoz Generic Drug Application Sandoz has received FDA approval for ANDA212069, expanding its generic drug portfolio and positioning the company to capture additio…